<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358263</url>
  </required_header>
  <id_info>
    <org_study_id>CORRIDA</org_study_id>
    <nct_id>NCT04358263</nct_id>
  </id_info>
  <brief_title>Is Real-time CGM Superior to Flash Glucose Monitoring</brief_title>
  <acronym>CORRIDA</acronym>
  <official_title>Comparison of CGM in Randomised Study of Real-time and Intermittently-scanned Systems in T1D With Normal Awareness of Hypoglycemia (CORRIDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigator's study is to compare real-time continuous glucose monitoring and
      flash glucose monitoring in adult patients with Type 1 Diabetes during 4-day training program
      focused on physical activity and over 4 weeks of follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time in hypoglycemic ranges</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>&lt;3,9 mmol/L (70 mg/dl) and &lt;3,0 mmol/L (54 mg/dl)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time in target ranges</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>3,9-10,0 mmol/L (70-180 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time in hyperglycemic ranges</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>(&gt;10,0 mmol/L (180 mg/dl) and &gt;13,9 mmol/L (250 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycemic variability</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Expressed as the coefficient of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean sensor glucose concentration</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Measured by rtCGM or isCGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life as assessed by validated questionnaire</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Assessed by The World Health Organization Quality of Life (WHOQOL)-BREF (Field Trial Version).
This questionnaire contains in total 26 questions in four Domains (Physical health, Psychological health, Social relationships, Environment). Scores in total range between 4-20 (each Domain 0-5), higher scores denote higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hypoglycaemia</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Requiring third-party assistance to treat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycated haemoglobin (HbA1c)</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Differences between HbA1c values in the initial period and after follow-up and differences of HbA1c between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>rtCGM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with use of the Guardian Connect Mobile system (real-time continuous glucose monitoring).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isCGM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with use of the FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)</intervention_name>
    <description>rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.</description>
    <arm_group_label>rtCGM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)</intervention_name>
    <description>rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.</description>
    <arm_group_label>isCGM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with T1D naive to rtCGM and isCGM

          -  Type 1 diabetes for &gt;2 years

          -  ≥ 18 years old

          -  CSII or MDI

          -  GOLD score &lt; 4, no history of severe hypoglycemia within last 6 month

          -  written informed consent prior to starting study related activity

        Exclusion Criteria:

          -  severe noncompliance

          -  severe diabetic retinopathy and/or macular edema

          -  lactation, pregnancy, intending to become pregnant during study

          -  condition likely to require MRI

          -  use of acetaminophen-containing medication

          -  unwillingness to use the study device for &gt;70% of time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Soupal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles University, Prague</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University</name>
      <address>
        <city>Prague</city>
        <state>Czech Republic</state>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract. 2008 Sep;14(6):750-6. Review.</citation>
    <PMID>18996798</PMID>
  </reference>
  <reference>
    <citation>Moser O, Tschakert G, Mueller A, Groeschl W, Pieber TR, Obermayer-Pietsch B, Koehler G, Hofmann P. Effects of High-Intensity Interval Exercise versus Moderate Continuous Exercise on Glucose Homeostasis and Hormone Response in Patients with Type 1 Diabetes Mellitus Using Novel Ultra-Long-Acting Insulin. PLoS One. 2015 Aug 28;10(8):e0136489. doi: 10.1371/journal.pone.0136489. eCollection 2015.</citation>
    <PMID>26317981</PMID>
  </reference>
  <reference>
    <citation>Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2010 Sep;39(3):641-54. doi: 10.1016/j.ecl.2010.05.003. Review.</citation>
    <PMID>20723825</PMID>
  </reference>
  <reference>
    <citation>Edelman SV, Argento NB, Pettus J, Hirsch IB. Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. Diabetes Care. 2018 Nov;41(11):2265-2274. doi: 10.2337/dc18-1150. Review.</citation>
    <PMID>30348844</PMID>
  </reference>
  <reference>
    <citation>Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D; DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378. doi: 10.1001/jama.2016.19975.</citation>
    <PMID>28118453</PMID>
  </reference>
  <reference>
    <citation>Šoupal J, Petruželková L, Flekač M, Pelcl T, Matoulek M, Daňková M, Škrha J, Svačina Š, Prázný M. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016 Sep;18(9):532-8. doi: 10.1089/dia.2016.0171. Epub 2016 Aug 2.</citation>
    <PMID>27482825</PMID>
  </reference>
  <reference>
    <citation>Šoupal J, Petruželková L, Grunberger G, Hásková A, Flekač M, Matoulek M, Mikeš O, Pelcl T, Škrha J Jr, Horová E, Škrha J, Parkin CG, Svačina Š, Prázný M. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study. Diabetes Care. 2020 Jan;43(1):37-43. doi: 10.2337/dc19-0888. Epub 2019 Sep 17.</citation>
    <PMID>31530663</PMID>
  </reference>
  <reference>
    <citation>Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Krӧger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018 Mar;61(3):539-550. doi: 10.1007/s00125-017-4527-5. Epub 2017 Dec 23.</citation>
    <PMID>29273897</PMID>
  </reference>
  <reference>
    <citation>Reddy M, Jugnee N, Anantharaja S, Oliver N. Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study. Diabetes Technol Ther. 2018 Nov;20(11):751-757. doi: 10.1089/dia.2018.0252. Epub 2018 Sep 28.</citation>
    <PMID>30265562</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Jan Soupal, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Continuous Glucose Monitoring</keyword>
  <keyword>Flash Glucose Monitoring</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Time in Range</keyword>
  <keyword>Physical Activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

